argenx SE ARGX-BE:Euronext Brussels
*Data is delayed | Exchange | EUR
Last | 5:37 PM CEST
695.40
+1.40 (+0.20%)
+1.40 (+0.20%)Volume
71,298
52 week range
456.60 - 810.00
- Open688.40
- Day High699.00
- Day Low674.80
- Prev Close694.00
- 52 Week High810.00
- 52 Week High Date11/20/25
- 52 Week Low456.60
- 52 Week Low Date07/04/25
Latest On argenx SE
Key Stats
- Market Cap43.245B
- Shares Out62.19M
- 10 Day Average Volume0.10M
- Dividend-
- Dividend Yield-
- Beta0.73
Latest On argenx SE
KEY STATS
- Open688.40
- Day High699.00
- Day Low674.80
- Prev Close694.00
- 52 Week High810.00
- 52 Week High Date11/20/25
- 52 Week Low456.60
- 52 Week Low Date07/04/25
- Market Cap43.245B
- Shares Out62.19M
- 10 Day Average Volume0.10M
- Dividend-
- Dividend Yield-
- Beta0.73
RATIOS/PROFITABILITY
- EPS (TTM)20.91
- P/E (TTM)33.25
- Fwd P/E (NTM)-
- EBITDA (TTM)1.134B
- ROE (TTM)20.15%
- Revenue (TTM)4.006B
- Gross Margin (TTM)89.46%
- Net Margin (TTM)31.95%
- Debt To Equity (MRQ)0.64%
EVENTS
- Earnings Date-
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREargenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to:...
Tim van Hauwermeiren
Non-Executive Chairman of the Board
Karen Massey
Chief Executive Officer, Executive Director
Karl Gubitz
Chief Financial Officer
Malini Moorthy
General Counsel, Corporate Secretary
Address
Laarderhoogtweg 25
Amsterdam
1101 EB
Netherlands